AtCor Medical - News 2006

At the annual general meeting of AtCor Medical chairman Donal O'Dwyer said that AtCor had made a great deal of progress to position itself for greater revenues from its SphygmoCor® system, which measures central blood pressure non-invasively.

Providing an update on AtCor's progress in the United States, AtCor chief executive officer Duncan Ross said the company had a strong market opportunity in the pharmaceutical sector, and was on track to more than double US revenues. AtCor has had a robust start to the financial year, gaining the single largest order in the company's history - a US$1.5 million sale to a mid-sized US pharmaceutical company. In addition, AtCor has more than doubled its sales opportunity pipeline from under US$1.0 million to over US$2.5 million.

Please click here to view the ASX/media release

AtCor Medical first quarter report - Appendix 4C

31 October 2006

AtCor Medical today releases its quarterly cash flow report for the period ending 30 September 2006. The company has $9,929,000 in cash and equivalents.

Please click here to view the ASX/media release

AtCor Medical Signs European Distributors. Appoints Asia-Pacific Sales and Marketing Manager.

11 October 2006

AtCor Medical today announced new distribution agreements to sell SphygmoCor in Spain, Switzerland, Benelux, Portugal and Scandinavia, and contract renewal with its distributors in United Kingdom/Ireland, Austria and Greece. The new agreements strengthen significantly AtCor's European marketing and distribution.

In addition, AtCor has focused its sales efforts in Asia-Pacific with the appointment of Tony Doherty to the newly created position of international sales and marketing manager. Mr. Doherty will be based in Sydney, and responsible for building sales outside the United States and Europe, particularly in Asia-Pacific. He has strong cardiovascular experience in Asian markets, and joins AtCor from Draeger and Siemens Medical, both world leading manufacturers of medical equipment.

Please click here to view the ASX/media release

AtCor Medical Annual General Meeting

5 October 2006

AtCor Medical today announced that the 2006 Annual General Meeting (AGM) of the Company will be held at Level 16, 60 Castlereagh St, Sydney, NSW 2000 on Thursday, 9 November, 2006 commencing at 11:00 am.

Please click here to view the ASX/media release

Investor Presentation

26 September 2006

AtCor Medical today released their Investor Presentation for 2006.

Please click here to view the ASX/media release

AtCor Medical appoints new CEO

25 September 2006

AtCor Medical today announced that Mr. Duncan Ross will become chief executive officer of the company at the annual general meeting on 9 November 2006.

Mr Ross is currently president and CEO of AtCor's North American business. He has over 23 years experience in the clinical diagnostics and life sciences device industry and for four years was president of Apogent Technologies' and Fisher Scientific Products' laboratory equipment group, the number two supplier in the global $2.8 billion laboratory equipment market.

Please click here to view the ASX/media release

ASX Preliminary year end information

6 September 2006

This has been a year of significant progress for AtCor Medical. We are able to report that a great deal has been accomplished and we have achieved many of the key milestones towards successful commercialisation of our SphygmoCor system.

Please click here to view the ASX/media release

US$1.5 million sale to US pharmaceutical company

31 August 2006

AtCor Medical has completed an agreement with a United States-based pharmaceutical company to supply SphygmoCor systems and clinical trial support services for a US multi-centre clinical trial. The total value of the contract is US$1.48 million.

Please click here to view the ASX/media release

AtCor Medical fourth quarter report - Appendix 4C

28 July 2006

AtCor Medical today releases its quarterly cash flow report for the period ending 30 June 2006. The company remains in a strong financial position with $11,811,000 in cash.

Please click here to view the ASX/media release

Shareholder's Newsletter

18 July 2006

AtCor Medical today releases its first Shareholder's Newsletter outlining the many exciting achievements for AtCor Medical since listing on the ASX last November.

Please click here to view the ASX/media release

Version 8 Software

10 July 2006

AtCor Medical is pleased to announce the release of SphygmoCor® Cardiovascular Management Suite Version 8, a new system software package that offers enriched clinical data and reporting capabilities, and provides a platform for development of future products, such as Heart Rate Variability.

Cardiovascular Management Suite clinical screens and reports provide central blood pressure parameters proven clinically significant in the recent CAFE and Strong Heart Studies (click here to view the CAFE and Strong Heart flyer), with these data reported in an expanded format from V7.1 against age- and gender-specific reference norms (click here to view the McEniery abstract).

For pulse wave velocity assessment, the Cardiovascular Management Suite reports PWV values – for the first time – against reference norms. This is especially important given the recent publication by Kullo, et al documenting the association between aortic pulse wave velocity and the presence and quantity of coronary artery calcium (click here to view the Kullo abstract).

Please refer to the detailed overview presentation that summarizes the new software package and provides a brief overview of the changes from Version 7.1. Click here to view the presentation.

Version 7.1 will remain available for supply and be supported for existing customers. For further enquiries regarding Version 8 or earlier versions of the software, please contact your local AtCor Medical representative, or send us an enquiry from our webpage here.

Medical Services Advisory Committee

16 June 2006

AtCor Medical has been advised by the Australian Medical Services Advisory Committee (MSAC) that the initial application for public funding has been unsuccessful.

Ross Harricks, AtCor Medical chief executive officer, said that the company would work with the Department of Health and Ageing and MSAC to lodge a new application.

Mr Harricks also stated that the MSAC decision would not affect the company’s progress. AtCor Medical is currently focused on building sales in the key United States market, and more than 900 SphygmoCor systems have been sold to research centres, hospitals and pharmaceutical companies worldwide, predominantly in the US and Europe. These include Mayo Clinic, Johns Hopkins University and Harvard Medical Centre.

Please click here to view the ASX/media release

AtCor Medical appoints President to build North American business

4 May 2006

AtCor Medical has appointed Duncan R Ross as President and CEO of its North American business, AtCor Medical Inc. In this newly-created role, Mr Ross will build and develop AtCor Medical’s sales and marketing program, which is being rolled out in the United States.

Mr Ross brings to AtCor over 23 years of experience in positions of increasing responsibility in the clinical diagnostics and life sciences device industry. Mr Ross was for four years President of Apogent Technologies' and Fisher Scientific Products Laboratory Equipment Group, the number two supplier in the global $2.8 billion laboratory equipment market.

Please click here to view the ASX/media release

AtCor Medical third quarter report - Appendix 4C

28 April 2006

AtCor Medical today releases its quarterly cash flow report for the period ending 31 March 2006. The company remains in a strong financial position with $13,280,000 in cash.

Please click here to view the ASX/media release

Major pharmaceutical company purchases SphygmoCor systems

21 March 2006

AtCor Medical Holdings Limited (ASX:ACG) today announced that it has received a significant order from US-based Novartis Pharmaceuticals Corporation, which uses the SphygmoCor system in its cardiovascular drug trials. This order, valued at approximately $300,000, follows Novartis’ purchase of SphygmoCor systems in 2005.

Please click here to view the ASX/media release

Major medical study publications endorse importance of SphygmoCor

13 March 2006

AtCor Medical Holdings Limited today announced that the Conduit Artery Function Evaluation (CAFE) study principal results published this week, and related commentaries in leading medical journals The Lancet and Circulation, provide a powerful endorsement for SphygmoCor.

Please click here to view the ASX/media release

AtCor Medical first half revenue up 40 percent - Investor Presentation

2 March 2006

AtCor Medical Holdings Limited today confirmed sales of $1.73 million for the six months to 31 December 2005, up 40 percent compared to the previous corresponding period.

Please click here to view the ASX/media release

AtCor Medical half-year financial report

2 March 2006

AtCor Medical Holdings Limited today released the financial report and accounts for the six months to 31 December 2005.

Please click here to view the ASX/media release

AtCor Medical second quarter report - Appendix 4C

30 January 2006

AtCor Medical Holdings Limited today announced sales of $1.73 million for the six months to 31 December 2005, up 40 percent compared to the previous corresponding period.

The company sold 95 SphygmoCor units to medical research centres and pharmaceutical companies worldwide, including a strong increase in sales in the United States. Sales included a significant order from Novartis, a major pharmaceutical company, for use in an international multi-centre clinical trial.

Please click here to view the ASX/media release